(Q37137848)

18 August 2017

1 reference

title

Calcium antagonists in cardiology: update on sustained-release drug delivery systems (English)

1 reference

18 August 2017

Calcium antagonists in cardiology: Update on sustained-release drug delivery systems (English)

1 reference

https://api.crossref.org/works/10.1002/CLC.4960141203

7 December 2022

1 reference

Cardiology and cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1002/CLC.4960141203

7 December 2022

author name string

E. L. Michelson

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1841019

7 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1841019

7 December 2022

publication date

1 December 1991

1 reference

full work available at URL

18 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fclc.4960141203

1 reference

https://api.crossref.org/works/10.1002/CLC.4960141203

https://onlinelibrary.wiley.com/doi/full/10.1002/clc.4960141203

7 December 2022

1 reference

https://api.crossref.org/works/10.1002/CLC.4960141203

7 December 2022

1 reference

18 August 2017

volume

14

1 reference

18 August 2017

issue

12

1 reference

18 August 2017

page(s)

947-950

1 reference

Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960141203

The effects of slow channel blockers and beta blockers on atrioventricular nodal conduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960141203

Once a day verapamil in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960141203

Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960141203

7 January 2021

The effect of diltiazem on mortality and reinfarction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960141203

7 January 2021

Calcium antagonists as antiatherogenic agents

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960141203

7 January 2021

Protective action of calcium channel antagonists in atherogenesis and experimental vascular injury

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960141203

7 January 2021

Calcium channel blockers and atherogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960141203

7 January 2021

The effect of prescribed daily dose frequency on patient medication compliance

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960141203

7 January 2021

The relationship of dose to the antihypertensive response of verapamil-sustained release in patients with mild to moderate essential hypertension. The Verapamil-SR Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960141203

7 January 2021

Influence of food on the bioavailability of a sustained-release verapamil preparation

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960141203

7 January 2021

Scientific rationale and clinical implications of sustained-release formulations

series ordinal

9

1 reference

https://api.crossref.org/works/10.1002/CLC.4960141203

Pharmacokinetics of once-daily verapamil: comparative bioavailability of two sustained-release formulations

7 December 2022

series ordinal

11

1 reference

https://api.crossref.org/works/10.1002/CLC.4960141203

7 December 2022

Identifiers

1 reference

18 August 2017

1 reference